Rein Therapeutics Inc. (RNTX)

NASDAQ: RNTX · Real-Time Price · USD
1.900
+0.030 (1.60%)
Mar 19, 2025, 9:30 AM EDT - Market open
1.60%
Market Cap 41.17M
Revenue (ttm) n/a
Net Income (ttm) -29.24M
Shares Out 21.67M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,700
Open 1.900
Previous Close 1.870
Day's Range 1.900 - 1.900
52-Week Range 1.610 - 7.420
Beta 2.25
Analysts n/a
Price Target n/a
Earnings Date May 14, 2025

About RNTX

Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company’s lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company’s pipeline also includes pre... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 15
Stock Exchange NASDAQ
Ticker Symbol RNTX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.